Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Published:2023-04 Issue:4 Volume:29 Page:253.e1-253.e9
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Yoon Dok Hyun^ORCID,Koh Youngil,Jung Miyoung,Kwak Jeong-Eun,Shin Eui-Cheol^ORCID,Hwang Yu Kyeong,Kim Won Seog^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference33 articles.

1. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy;Rovira;Ann Hematol,2015

2. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives;Lo Nigro;Ann Transl Med,2019

3. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia;Levine;J Immunother Cancer,2021

4. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study;Bishop;Blood,2021

5. Cancer immunotherapy based on natural killer cells: current progress and new opportunities;Hu;Front Immunol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells;Cell Stem Cell;2024-09

2. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

3. Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective;Biomarker Research;2024-07-17

4. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy;Frontiers in Immunology;2023-11-24